APRE Aprea Therapeutics

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
EN
14/10/2020

Underlying

APREAprea Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aprea Therapeutics

 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Con...

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date/ time: Tuesday, September 9 at 3:30 PM...

August 28, 2025 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and P...

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 million in cash and cash equivalents as of June 30, 2025 DOYLESTOWN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer ...

August 12, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
APRE APREA THERAPEUTICS
08/12/25 August 12, 2025 1 EN
Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll
APRE APREA THERAPEUTICS
06/25/25 June 25, 2025 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Cli...

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APR...

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch